The Latest Breaking News from Eisai

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

Eisai Co.’s breakthrough Alzheimer’s drug — the first to show it slows the brain-destroying disease — is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and complicated safety testing requirements.

As advanced remedies emerge, the chief executive of Alzheimer’s Research UK warns sufferers could miss out as the health service struggles to cope

The Food and Drug Administration (FDA) has approved the much awaited drug Leqembi which has been shown to slow the cognitive decline caused by Alzheimer’s, the most common type of dementia

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators Thursday, a move expected to widen access to the first drug cleared based on its ability to slow progression of the mind-robbing disease.

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

U.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.